Nivolumab Plus Chemo Improved OS and PFS in Front-Line ES-SCLC
Written by
Cancer Network
Published
0
comments
0
min
The median PFS and OS were 5.5 months and 11.2 months with nivolumab plus carboplatin/cisplatin and etoposide in patients with small cell lung cancer.